<DOC>
	<DOC>NCT00887822</DOC>
	<brief_summary>This 2 arm study will compare the efficacy and safety of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin in participants who have not received prior chemotherapy for advanced or metastatic gastric cancer. Participants will be randomized to one of two treatment groups Bevacizumab + Capecitabine/Cisplatin (experimental arm) or Placebo + Capecitabine/Cisplatin (control arm).</brief_summary>
	<brief_title>A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically confirmed adenocarcinoma of the stomach or gastrooesophageal junction with inoperable, locally advanced or metastatic disease, not amenable to curative therapy Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2 Measurable disease or nonmeasurable but evaluable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST) Previous chemotherapy for locally advanced or metastatic gastric cancer Previous platinum or antiangiogenic therapy Radiotherapy within 28 days of randomization Evidence of Central Nervous System (CNS) metastasis at baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>